Does the addition of ticagrelor to aspirin reduce the risk of ischemic events following mild acute ischemic stroke or high-risk transient ischemic attack?

BEEM Bottom Line

Why is this study important?

Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin (ASA) given within 24 hours of acute onset minor acute ischemic stroke (AIS) or high-risk transient ischemic attack (TIA) reduces the risk of subsequent stroke during the next 30 to 90 days (number needed to treat [NNT] = 53).[1] [2] Unlike clopidogrel, ticagrelor is a direct platelet inhibitor and, therefore, potentially more effective. This trial assesses DAPT with ticagrelor and ASA for mild acute, non-embolic AIS or high-risk TIA.

Which, if any, threats to validity are most likely to have an impact on the results and how?

Thank you for your interest in the BEEM Journal!

To read the rest of this article or to access the entire collection of BEEM Critical Appraisals, please purchase a subscription at the link below.

If you would like a pre-view, click here to view some sample articles

Premium Content Available Through Subscription

BEEM is a knowledge translation project which aims to extract the most recent, EM relevant, and valid evidence from the volumes of available medical research and deliver it to EM practitioners in an easily consumable format to help guide their clinical practice. This valuable distilled information provided by BEEM is available through BEEM's accredited CME courses or through our online journal.

A BEEM Journal Subscription will provide you with unlimited access to our entire collection of Critical Appraisals for 1 year.